CAMBRIDGE, Mass.--Vertex Pharmaceuticals and Novartis Pharma have formed an alliance to discover, develop, and commercialize small molecule drugs directed at targets in protein kinases. The collaboration could be worth as much as $800 million to Vertex if it successfully discovers and develops eight compounds.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.